CAPRI细胞免疫疗法辅治32例三阴性乳腺癌临床观察

Clinical observation of CAPRI cell immunotherapy for 32 triple negative breast cancer: 32 cases

目的观察CAPRI细胞免疫疗法(将链式激活的免疫细胞回输到患者体内,从而达到杀伤肿瘤细胞目的的治疗过程)辅助治疗三阴乳腺癌(TNBC)的临床疗效。方法 64例TNBC患者随机分为治疗组和对照组,每组32例。对照组采用根治性手术及常规辅助化放疗,治疗组在此基础上加用CAPRI细胞免疫治疗。随访时间从2011年8月至2016年2月或患者死亡时间。观察两组随访期间局部复发和远处转移的发生情况,对比两组无病生存率及总生存率。结果随访30个月,治疗组局部复发和远处转移的发生率较对照组低(21.9%vs 46.9%,P<0.05),无病生存率明显高于对照组(P<0.05);总生存率略高于对照组,但差异尚无统计学意义(84.4%vs 81.2%,P>0.05)。结论 CAPRI细胞免疫疗法在短期内可降低TNBC患者肿瘤的局部复发与远处转移的发生率,而其对总生存率的影响有待临床进一步探讨。

Objective To study the clinical effect of CARPI （cascade primed immune cells） cell immunotherapy for triple negative breast cancer （TNBC）. Methods 64 TNBC patients were randomly divided into two groups, 32 cases in each group. Control Group received radical surgery and routine adjuvant chemoradiotherapy while Treatment Group received radical surgery and routine adjuvant chemoradiotherapy combined with CAPRI cell immunotherapy. The patients were followed up from August 2011 to February 2016 or death time. The local recurrence and distant metastasis of both groups during the follow-up were observed, and the disease-free survival （DFS） and overall survival （OS） were compared. Results After 30 months＇ follow-up, Treatment Group had an incidence of local recurrence and distant metastasis lower than those of Control Group （21.9% vs 46.9%, P〈0.05）, and a DFS significantly higher than Control Group （P〈0.05）; Treatment Group had an OS slightly higher than Control Group, but there was no statistical difference （84.4% vs 81.2%, P〉0.05）. Conclusion CAPRI cell immunotherapy could reduce the local recurrence and distance metastasis in TNBC within a short period, but its effect on OS remains to be further explored.